[go: up one dir, main page]

FI973002L - Terapeuttinen yhdiste - rasvahappokonjugaatit - Google Patents

Terapeuttinen yhdiste - rasvahappokonjugaatit Download PDF

Info

Publication number
FI973002L
FI973002L FI973002A FI973002A FI973002L FI 973002 L FI973002 L FI 973002L FI 973002 A FI973002 A FI 973002A FI 973002 A FI973002 A FI 973002A FI 973002 L FI973002 L FI 973002L
Authority
FI
Finland
Prior art keywords
fatty acid
therapeutic compound
acid conjugates
conjugates
therapeutic
Prior art date
Application number
FI973002A
Other languages
English (en)
Swedish (sv)
Other versions
FI973002A0 (fi
FI973002A7 (fi
Inventor
Robert George Whittaker
Veronika Judith Bender
Wayne Gerrard Reilly
Minoo Moghaddam
Original Assignee
Commw Scient Ind Res Org
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPN0583A external-priority patent/AUPN058395A0/en
Priority claimed from AUPN0584A external-priority patent/AUPN058495A0/en
Priority claimed from AUPN0582A external-priority patent/AUPN058295A0/en
Priority claimed from AUPN0581A external-priority patent/AUPN058195A0/en
Priority claimed from AUPN0585A external-priority patent/AUPN058595A0/en
Priority claimed from AUPN0580A external-priority patent/AUPN058095A0/en
Priority claimed from AUPN0586A external-priority patent/AUPN058695A0/en
Application filed by Commw Scient Ind Res Org filed Critical Commw Scient Ind Res Org
Publication of FI973002A0 publication Critical patent/FI973002A0/fi
Publication of FI973002L publication Critical patent/FI973002L/fi
Publication of FI973002A7 publication Critical patent/FI973002A7/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/06Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D489/00Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI973002A 1995-01-16 1996-01-15 Terapeuttinen yhdiste - rasvahappokonjugaatit FI973002A7 (fi)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
AUPN0583A AUPN058395A0 (en) 1995-01-16 1995-01-16 Therapeutic conjugates 5
AUPN0584A AUPN058495A0 (en) 1995-01-16 1995-01-16 Therapeutic conjugates 6
AUPN0582A AUPN058295A0 (en) 1995-01-16 1995-01-16 Therapeutic conjugates 4
AUPN0581A AUPN058195A0 (en) 1995-01-16 1995-01-16 Therapeutic conjugates 3
AUPN0585A AUPN058595A0 (en) 1995-01-16 1995-01-16 Therapeutic conjugates 7
AUPN0580A AUPN058095A0 (en) 1995-01-16 1995-01-16 Therapeutic conjugates 2
AUPN0586A AUPN058695A0 (en) 1995-01-16 1995-01-16 Therapeutic conjugates 8
PCT/AU1996/000015 WO1996022303A1 (en) 1995-01-16 1996-01-15 Therapeutic compound - fatty acid conjugates

Publications (3)

Publication Number Publication Date
FI973002A0 FI973002A0 (fi) 1997-07-15
FI973002L true FI973002L (fi) 1997-08-19
FI973002A7 FI973002A7 (fi) 1997-08-19

Family

ID=27560724

Family Applications (1)

Application Number Title Priority Date Filing Date
FI973002A FI973002A7 (fi) 1995-01-16 1996-01-15 Terapeuttinen yhdiste - rasvahappokonjugaatit

Country Status (10)

Country Link
US (3) US5952499A (fi)
EP (1) EP0804459A4 (fi)
JP (1) JPH11502509A (fi)
BR (1) BR9607492A (fi)
CA (1) CA2210500A1 (fi)
FI (1) FI973002A7 (fi)
NO (1) NO973283L (fi)
NZ (1) NZ298712A (fi)
RU (1) RU2166512C2 (fi)
WO (1) WO1996022303A1 (fi)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
AUPN741696A0 (en) * 1996-01-05 1996-01-25 Commonwealth Scientific And Industrial Research Organisation Delivery of nucleic acids ii
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
DE19631189A1 (de) * 1996-08-02 1998-02-05 Max Delbrueck Centrum Neuartige kationische Amphiphile für den liposomalen Gentransfer
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
JP2002523071A (ja) * 1998-08-31 2002-07-30 バイオジェン インコーポレイテッド 記憶エフェクターt細胞を調整する方法と組成物
AUPP751398A0 (en) * 1998-12-04 1999-01-07 Commonwealth Scientific And Industrial Research Organisation Methotrexate derivatives
US7235583B1 (en) * 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
US7238368B2 (en) 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
CA2369595C (en) 1999-04-23 2010-10-05 Alza Corporation Conjugate having a cleavable linkage for use in a liposome
US6765019B1 (en) 1999-05-06 2004-07-20 University Of Kentucky Research Foundation Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
CN1191861C (zh) * 1999-05-24 2005-03-09 三共株式会社 含有抗Fas抗体的药物组合物
GB9930026D0 (en) * 1999-12-21 2000-02-09 Univ Sheffield Novel compounds of unsaturated fatty acids
US6485740B1 (en) * 2000-03-14 2002-11-26 Yutoku Pharmaceutical Ind., Co., Ltd. Transdermal methotrexate preparations
WO2005032474A2 (en) * 2003-09-30 2005-04-14 New River Pharmaceuticals Inc. Pharmaceutical compositions for prevention of overdose or abuse
EP1423107B1 (en) * 2001-03-23 2012-05-09 Luitpold Pharmaceuticals, Inc. Fatty alcohol drug conjugates
EP1427407A4 (en) * 2001-03-23 2005-05-11 Luitpold Pharm Inc FAT AMIN DRUG CONJUGATES
IL158882A0 (en) * 2001-06-05 2004-05-12 Control Delivery Sys Inc Sustained-release analgesic compounds
CA2454618C (en) * 2001-07-24 2012-04-03 Biogen Idec Ma, Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
US7125568B2 (en) 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
US7045543B2 (en) 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070172478A1 (en) * 2004-02-06 2007-07-26 Astellas Us Llc Methods of treating skin disorders
MXPA06012744A (es) * 2004-05-04 2007-02-19 Genaissance Pharmaceutical Inc Marcadores de haplotipo y metodos para utilizarlos en la determinacion de la respuesta al tratamiento.
US7662921B2 (en) * 2004-05-07 2010-02-16 Astellas Us Llc Methods of treating viral disorders
US20060078580A1 (en) 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US7740875B2 (en) * 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
CA2592320C (en) 2004-12-22 2015-11-24 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7724373B2 (en) * 2005-12-16 2010-05-25 Indiana University Research & Technology Corporation Sub-micron surface plasmon resonance sensor systems
DE102006035083A1 (de) * 2006-07-28 2008-01-31 medac Gesellschaft für klinische Spezialgeräte mbH Proteinbindende Methotrexat-Derivate und diese enthaltende Arzneimittel
KR101443573B1 (ko) 2006-10-12 2014-11-03 비에이치아이 리미티드 파트너쉽 3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클
WO2009121018A2 (en) * 2008-03-27 2009-10-01 University Of Kentucky Research Foundation Opioid-nornicotine codrugs for pain management
US8710070B2 (en) * 2008-03-27 2014-04-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
WO2010035261A2 (en) 2008-09-29 2010-04-01 Ben Gurion University Of The Negev Research And Development Authority Amyloid beta-peptides and methods of use thereof
MX2011004095A (es) * 2008-10-17 2011-07-28 Pharmacofore Inc Composiciones farmaceuticas con liberacion atenuada de opioides fenolicos.
US8603999B2 (en) 2008-12-05 2013-12-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs
US20100240883A1 (en) * 2009-03-18 2010-09-23 Nian Wu Lipid-drug conjugates for drug delivery
DK2531221T3 (da) 2010-02-03 2019-06-17 Nanopet Pharma Gmbh Polyanioniske multivalente makromolekyler til intracellulær målretning af proliferation og proteinsyntese
WO2013063204A1 (en) 2011-10-26 2013-05-02 Kempharm, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof
EP3226907A1 (en) 2014-12-02 2017-10-11 Kempharm, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods and making and use thereof
WO2017106957A1 (en) * 2015-12-23 2017-06-29 The University Of British Columbia Lipid-linked prodrugs
US20230137562A1 (en) 2017-06-07 2023-05-04 Adrx, Inc. Tau aggregation inhibitors
AU2018318319A1 (en) 2017-08-18 2020-02-20 Adrx, Inc. Tau aggregation peptide inhibitors
RU2713838C1 (ru) * 2019-04-23 2020-02-07 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) Способ анестезиологического обеспечения при селективной доставке химиопрепарата к сетчатке глаза при лечении интраокулярной ретинобластомы у детей

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3686238A (en) * 1970-01-19 1972-08-22 Syntex Corp Glycerol esterified with 2-naphthyl-acetic acids and fatty acids
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4939174A (en) * 1988-02-26 1990-07-03 Shashoua Victor E Appetite suppression with dopamine-fatty acid conjugates
DE3904119A1 (de) * 1989-02-11 1990-08-16 Hoechst Ag Polymerfixiertes methotrexat, verfahren zur herstellung und verwendung
EP0506748B1 (en) * 1989-12-22 1995-12-13 Commonwealth Scientific And Industrial Research Organisation Amino acids, peptides or derivatives thereof coupled to fats
US5583198A (en) * 1989-12-22 1996-12-10 Commonwealth Scientific And Industrial Research Organization Amino acids, peptides or derivatives thereof coupled to fats
JPH0421694A (ja) * 1990-05-16 1992-01-24 Asahi Chem Ind Co Ltd 新規なヌクレオシド―リン脂質複合体
EP0576605A4 (en) * 1991-03-19 1994-06-08 Vithal J Rajadhyaksha Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers
DE69230855D1 (de) * 1991-07-26 2000-05-04 Commw Scient Ind Res Org System der bereitstellung eines impfstoffes auf peptidbasis, das sein eigenes adjuvans bildet, und seine herstellung
DE4310516A1 (de) * 1993-02-09 1994-08-11 Boehringer Mannheim Gmbh Lipoprotein (a)-Peptide und deren Verwendung
DE4311987A1 (de) * 1993-04-07 1994-10-13 Schering Ag Neue Glucocorticoide
NZ269773A (en) * 1993-08-02 1997-11-24 Commw Scient Ind Res Org Therapeutic compound conjugates; such conjugates comprise a compound bound to one to three acyl groups derived from fatty acids

Also Published As

Publication number Publication date
CA2210500A1 (en) 1996-07-25
EP0804459A1 (en) 1997-11-05
US6281376B1 (en) 2001-08-28
US20030023104A1 (en) 2003-01-30
BR9607492A (pt) 1999-06-29
NZ298712A (en) 1998-12-23
FI973002A0 (fi) 1997-07-15
EP0804459A4 (en) 1999-05-26
WO1996022303A1 (en) 1996-07-25
NO973283L (no) 1997-09-08
JPH11502509A (ja) 1999-03-02
FI973002A7 (fi) 1997-08-19
NO973283D0 (no) 1997-07-15
US5952499A (en) 1999-09-14
RU2166512C2 (ru) 2001-05-10

Similar Documents

Publication Publication Date Title
FI973002A0 (fi) Terapeuttinen yhdiste - rasvahappokonjugaatit
ATE211131T1 (de) Arylsulfonylaminohydroxamsäurederivate
BR9602637A (pt) Cateter
BR9610153A (pt) Formulações farmacêuticas
BR9611626A (pt) Formulações farmacéuticas
DE69627539D1 (de) Verpackungsfreie bioelektrode
DE69630305D1 (de) Elektrodenkatheter
FI971279L (fi) Lääkkeitä
BR9602635A (pt) Conjunto de cateter
NO963625D0 (no) Kateter
DK0822982T3 (da) Cyclomaltodextringlucanotransferasevarianter
DE69606550D1 (de) Medizinischen verbindungsanordnung
DE69517172D1 (de) Therapeutische verbindungen
DE69606053D1 (de) Modifizierte fluorsulfonsäure
BR9600809A (pt) Medicamento
NO972868D0 (no) Oligonukleotid-dendrimer konjugater
ITMI941169A0 (it) Formulazioni farmaceutiche
EP0837863A4 (en) DISODIUM ALENDRONATE PREPARATIONS
FI970195L (fi) Trifluormetyylikinoliinikarboksyylihappojohdannainen
KR960026722U (ko) 견인치료기
DK0818964T3 (da) Doseringsstift
DE69616554D1 (de) Sialinsäure-derivate
DE59610423D1 (de) Partikulare arzneiform
FI973755A7 (fi) Viistokantaniitti
KR970005245A (ko) 교합기